Psychedelics Today, Author at PsyNews.com

Home Authors Posts by admin

2176 POSTS 0 COMMENTS

https://psynews.com

Breathwork, Holding Space, and the Healing Power of Connection: Documenting the...

Exclusive: David Hough on Lykos’ Path to Resubmission

Psychedelics and Addiction Recovery: Microdosing and Redefining the Path to Sobriety

Pα+ Psychedelic Bulletin #171: Lykos Criticises AdComm Process; Cybin’s Plan to...

Is Psychedelic-Assisted Therapy at a Crossroads? Exploring What’s Next for Lykos...

Empathy and Agency: Why Psychedelic Practitioners Need to be Trauma-Informed

What Does FDA Expect from Lykos’ Next Phase 3 MDMA Study?...

The Illinois CURE Act: Shaping the Future of Psychedelic Policy

Regenerative Economics and Psychedelics: Creating More Connected Leadership

What Does FDA Expect from Lykos’ Next Phase 3 MDMA Study?...

1...101112...218 Page 11 of 218

EDITOR PICKS

UK Psychedelic Research Hindered by Red Tape, Experts Tell Lawmakers in...

MDMA for Active-Duty Troops: Aaron Wolfgang on DoD’s Unprecedented Study

Opinions: PrEP’s Rollout Offers a Roadmap for Prescription Psychedelics

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

admin

Breathwork, Holding Space, and the Healing Power of Connection: Documenting the...

Exclusive: David Hough on Lykos’ Path to Resubmission

Psychedelics and Addiction Recovery: Microdosing and Redefining the Path to Sobriety

Pα+ Psychedelic Bulletin #171: Lykos Criticises AdComm Process; Cybin’s Plan to...

Is Psychedelic-Assisted Therapy at a Crossroads? Exploring What’s Next for Lykos...

Empathy and Agency: Why Psychedelic Practitioners Need to be Trauma-Informed

What Does FDA Expect from Lykos’ Next Phase 3 MDMA Study?...

The Illinois CURE Act: Shaping the Future of Psychedelic Policy

Regenerative Economics and Psychedelics: Creating More Connected Leadership

What Does FDA Expect from Lykos’ Next Phase 3 MDMA Study?...

EDITOR PICKS

UK Psychedelic Research Hindered by Red Tape, Experts Tell Lawmakers in...

MDMA for Active-Duty Troops: Aaron Wolfgang on DoD’s Unprecedented Study

Opinions: PrEP’s Rollout Offers a Roadmap for Prescription Psychedelics

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY